FTRE vs. EXAS, RDNT, GH, VCYT, VRDN, CDNA, CSTL, FLGT, CELC, and SERA
Should you be buying Fortrea stock or one of its competitors? The main competitors of Fortrea include Exact Sciences (EXAS), RadNet (RDNT), Guardant Health (GH), Veracyte (VCYT), Viridian Therapeutics (VRDN), CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), and Sera Prognostics (SERA). These companies are all part of the "medical laboratories" industry.
Fortrea (NASDAQ:FTRE) and Exact Sciences (NASDAQ:EXAS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
In the previous week, Fortrea had 9 more articles in the media than Exact Sciences. MarketBeat recorded 22 mentions for Fortrea and 13 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 0.85 beat Fortrea's score of 0.72 indicating that Exact Sciences is being referred to more favorably in the news media.
88.8% of Exact Sciences shares are held by institutional investors. 0.1% of Fortrea shares are held by insiders. Comparatively, 1.4% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Exact Sciences received 942 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 72.46% of users gave Exact Sciences an outperform vote while only 40.00% of users gave Fortrea an outperform vote.
Fortrea has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.
Fortrea presently has a consensus target price of $32.78, suggesting a potential upside of 29.10%. Exact Sciences has a consensus target price of $95.40, suggesting a potential upside of 109.90%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Exact Sciences is more favorable than Fortrea.
Fortrea has a net margin of -4.11% compared to Exact Sciences' net margin of -9.48%. Fortrea's return on equity of 4.76% beat Exact Sciences' return on equity.
Summary
Exact Sciences beats Fortrea on 10 of the 18 factors compared between the two stocks.
Get Fortrea News Delivered to You Automatically
Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
